Tobam Purchases 9,656 Shares of DexCom, Inc. $DXCM

Tobam raised its position in shares of DexCom, Inc. (NASDAQ:DXCM) by 16.1% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 69,604 shares of the medical device company’s stock after buying an additional 9,656 shares during the period. Tobam’s holdings in DexCom were worth $4,620,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. CVA Family Office LLC increased its position in shares of DexCom by 48.5% in the fourth quarter. CVA Family Office LLC now owns 450 shares of the medical device company’s stock valued at $30,000 after acquiring an additional 147 shares during the period. MCF Advisors LLC purchased a new stake in shares of DexCom during the fourth quarter worth about $32,000. ORG Partners LLC boosted its holdings in shares of DexCom by 124.3% during the fourth quarter. ORG Partners LLC now owns 507 shares of the medical device company’s stock worth $34,000 after purchasing an additional 281 shares during the period. DV Equities LLC bought a new stake in shares of DexCom in the fourth quarter worth about $36,000. Finally, Spire Wealth Management grew its stake in shares of DexCom by 113.8% in the fourth quarter. Spire Wealth Management now owns 573 shares of the medical device company’s stock worth $38,000 after purchasing an additional 305 shares during the last quarter. Institutional investors own 97.75% of the company’s stock.

DexCom Price Performance

DXCM stock opened at $72.47 on Friday. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.95 and a quick ratio of 1.64. DexCom, Inc. has a 1 year low of $54.11 and a 1 year high of $89.98. The firm has a 50-day moving average of $67.07 and a 200 day moving average of $67.92. The company has a market cap of $27.96 billion, a P/E ratio of 30.97, a PEG ratio of 1.13 and a beta of 1.45.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings data on Thursday, April 30th. The medical device company reported $0.56 earnings per share for the quarter, beating the consensus estimate of $0.47 by $0.09. DexCom had a return on equity of 33.33% and a net margin of 19.31%.The business had revenue of $1.19 billion for the quarter, compared to analysts’ expectations of $1.17 billion. During the same period in the previous year, the firm posted $0.32 EPS. The business’s revenue was up 15.0% on a year-over-year basis. On average, sell-side analysts forecast that DexCom, Inc. will post 2.58 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on the company. Evercore upgraded DexCom from an “in-line” rating to an “outperform” rating and set a $90.00 price target on the stock in a report on Tuesday, March 24th. Citigroup reiterated a “buy” rating and issued a $84.00 price objective (up from $79.00) on shares of DexCom in a research report on Thursday, May 28th. UBS Group set a $95.00 target price on DexCom in a research note on Wednesday, June 10th. Bank of America decreased their target price on DexCom from $100.00 to $80.00 and set a “buy” rating for the company in a report on Monday, May 18th. Finally, Barclays reaffirmed an “underweight” rating and issued a $64.00 price target (down from $67.00) on shares of DexCom in a research note on Monday, May 18th. Three analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $84.83.

Insider Buying and Selling

In other news, EVP Jon Coleman sold 4,912 shares of the firm’s stock in a transaction that occurred on Wednesday, June 3rd. The stock was sold at an average price of $73.00, for a total value of $358,576.00. Following the completion of the transaction, the executive vice president owned 100,361 shares in the company, valued at $7,326,353. This trade represents a 4.67% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bridgette P. Heller sold 1,012 shares of DexCom stock in a transaction that occurred on Tuesday, May 12th. The shares were sold at an average price of $60.01, for a total value of $60,730.12. Following the sale, the director owned 25,007 shares in the company, valued at $1,500,670.07. This represents a 3.89% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 46,694 shares of company stock worth $3,343,977 over the last quarter. Company insiders own 0.28% of the company’s stock.

DexCom Company Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.